

felodipine, benazepril HCl, ramipril, irbesartan, verapamil HCl, bisoprolol fumarate and hydrochlorothiazide, amlodipine and benazepril HCl, clonidine, candesartan, cilexetil, diltiazem, nicardipine, imidapril, trandolapril, eprosartan mesylate, nilvadipine, verapamil HCl, temocapril, prazosin HCl, isradipine, cilazapril, celiprolol, bisoprolol, betazolol HCl, ramipril, nisoldipine, lisinopril, trandolapril, and nisoldipine.

24. (Withdrawn) The encapsulated product of claim 23, wherein said therapeutic is nifedipine.

**REMARKS**

Claims 1-24 are currently pending in the present application, with claims 8-24 having been provisionally withdrawn by the Examiner as being directed to a non-elected species. Thus, claims 1-7 are currently under consideration pending the allowance of a generic claim. Claim 1 is an independent claim drawn to an encapsulated product with claims 2-7 depending therefrom and adding further limitations. The claims have been amended to better clarify the subject matter contained therein. Applicant submits that no new matter within the meaning of 35 U.S.C. 132 is added by the claim amendments

Claims 1-7 stand rejected under 35 U.S.C. §103(a) as being

obvious over Jerussi et al. (U.S. Patent No. 6,197,828) in view of Amey et al. (U.S. Patent No. 6,245,350) for the inclusion of tablets into a capsule.

These remarks are presented in the expectation that they place this application in condition for allowance. Accordingly, entry of the remarks is respectfully requested.

**Rejection of Claims 1-7 under 35 U.S.C 103(a)**

Claims 1-7 stand rejected under 35 U.S.C. §103(a) as being obvious over Jerussi et al. (U.S. Patent No. 6,197,828) in view of Amey et al. (U.S. Patent No. 6,245,350) for the reasons set forth in the Office Action.

**RESPONSE**

Applicant respectfully traverses this rejection and requests reconsideration and withdrawal thereof.

Applicant respectfully submits that the references of record, the Jerussi et al. patent and the Amey et al. patent, do not teach or suggest Applicant's inventive subject matter as a whole, as recited in the claims. Further, there is no teaching or suggestion in this reference that would lead one of ordinary skill in the art to modify the reference to arrive at the subject of the amended

claims with any expectation of success at the time the invention was made.

The U.S. Supreme Court in Graham v. John Deere Co., 148 U.S.P.Q. 459 (1966) held that non-obviousness was determined under § 103 by (1) determining the scope and content of the prior art; (2) ascertaining the differences between the prior art and the claims at issue; (3) resolving the level of ordinary skill in the art; and (4) inquiring as to any objective evidence of nonobviousness.

To establish a *prima facie* case of obviousness, the Examiner must establish: (1) that some suggestion or motivation to modify the references exists; (2) a reasonable expectation of success; and (3) that the prior art references teach or suggest all the claim limitations. Amgen, Inc. v. Chugai Pharm. Co., 18 USPQ2d 1016, 1023 (Fed. Cir. 1991); In re Fine, 5 USPQ2d 1596, 1598 (Fed. Cir. 1988); In re Wilson, 165 USPQ 494, 496 (C.C.P.A. 1970).

A *prima facie* case of obviousness must also include a showing of the reasons why it would be obvious to modify the references to produce the present invention. See Ex parte Clapp, 277 USPQ 972, 973 (Bd. Pat. App. & Inter. 1985). The Examiner bears the initial burden to provide some convincing line of reasoning as to why the artisan would have found the claimed invention to have been obvious in light of the teachings. Id. at 974.

**A. The present inventive subject matter**

As is indicated above, independent claim 1 is drawn to a pharmaceutical product **consisting essentially of** a therapeutically effective amount of a pharmaceutical, at least one compressible material, and at least one lubricating material. The encapsulated product is **in the form of a caplet having a diameter from about 1 millimeter to about 7 millimeters and a length from about 1 millimeter to about 7 millimeters**. The remaining claims depend from claim 1 and add further limitations thereto.

Claim 1 has been amended to clarify that the current product, while in a non-limiting example of one embodiment could be encapsulated or coated with a coating, does not have to be encapsulated in order to achieve the presently desired characteristics.

**B. The prior art**

As has been indicated in the previous responses, the Jerussi et al. patent (U.S. Patent No. 6,197,828) discloses methods of preparing, and compositions comprising, derivatives of (+) venlafaxine. The dosage form may include tablets, caplets, troches, lozenges, dispersions, suspensions, suppositories, ointments, cataplasms, pastes, powders, dressings, creams,

plasters, solutions, capsules, soft elastic gelatin capsules, and patches.

Likewise, the Amey et al. patent (U.S. Patent No. 6,245,350) discloses a process for encapsulation of caplets in a capsule and solid dosage forms obtainable by the process. The Amey et al. patent discloses a process for encapsulation of a caplet in a capsule by cold shrinking together capsule parts, which are filled with the caplets.

**C. The differences between the claimed subject matter  
and the prior art**

The differences between applicant's inventive subject matter and the cited reference is apparent from their independent and distinct disclosures and claim. Claim 1 (and the claims which depend therefrom) **consist essentially of** an encapsulated product **in the form of a caplet having a diameter from about 1 millimeter to about 7 millimeters and a length from about 1 millimeter to about 7 millimeters.**

Applicant respectfully reiterates that Jerussi et al. and Amey et al. fail to teach or suggest an encapsulated product comprising the novel combinations of ingredients and sizes. This is

especially true given the unique nature of the sizes of the claimed products. In support of this position, Applicant respectfully submits herewith a Declaration under 37 C.F.R. 1.132 providing further distinguishing characteristics between the present claims and the disclosures of the cited prior art.

As is provided in the accompanying declaration, the innovative aspect of the present claims is the size of the delivery system, namely the caplets having the dimensions set forth in the claims. Applicant has determined that a surprisingly high dose of pharmaceutical is able to be incorporated into the small dosage form resulting in more accurate release and dosing of a mammal when administered thereto. The smaller dosage form, with the ingredients uniformly dispersed throughout the caplet (as opposed to the active ingredient being applied in a coating to a sugar core) results in a superior delivery profile. The smaller size provides a greater surface area for the active ingredient to be released faster into the system of the mammal.

Furthermore, better and more accurately reproducible controlled dosing of active ingredients has been desired in the healthcare industry, and the presently claimed product is one product that allows for more accurate and controlled dosing of patients. The faster delivery as a result of the smaller size of the dosing unit also allows for better response and compliance by

the patient to whom the pharmaceutical active ingredients are being administered.

With the above as a basis, Applicant again respectfully reiterates that the Jerussi et al. patent **fails to disclose the dosage form of a caplet having a diameter from about 1 millimeter to about 7 millimeters and a length from about 1 millimeter to about 7 millimeters**. This important limitation is found in independent claim 1, and thus also in the dependent claim, and since the Jerussi et al. patent **fails to disclose this limitation**, Applicant submits that the Jerussi et al. patent **fails to render obvious claims 1-7**, since there is no motivation to modify the reference in an attempt to achieve the presently claimed inventive subject matter.

The Examiner argues in the Office Action on Page 3 that "...there is nothing in the Jerussi reference or the Amey reference that materially affect the basic and novel characteristic(s) of the claimed invention." Applicant respectfully disagrees with this assertion. As is indicated above and in the attached declaration, the unique properties of the presently claimed invention are a result from the size of the dosing unit. Neither reference discloses the small size for the dosing unit, and therefore, the references fail to disclose the limitation that provides the

uniqueness of the presently claimed inventive subject matter. The size imparts the unique features of the invention, and neither reference discusses the size of the dosing unit.

In particular, the Examiner relies on the Amey et al. patent for the proposition that the caplets may be encapsulated in a capsule. However, Applicant respectfully submits that the Amey et al. patent **fails to cure the deficiency** of the Jerussi et al. patent. In other words, Applicant respectfully submits that the Amey et al. patent also **does not disclose** the limitation regarding the size of the caplets as claimed in the present claims under consideration.

Thus, assuming *arguendo*, that the Jerussi et al. patent and the Amey et al. patents were combined in an attempt to achieve the presently claimed subject matter, Applicant respectfully submits that the combination of the patents **would still not disclose** all of the limitations of the present claims. **In particular, the combination of the patents would not include the limitation regarding the size of the caplets.**

Since this deficiency would still be present, Applicant respectfully submits that the Examiner has failed to prove a *prima facie* case of obviousness, which requires that the prior art references teach or suggest all of the claimed limitations. It is



clear that the prior art references cited by the Examiner fail to accomplish this, and thus the claims are not obvious over the references. Applicant, therefore, respectfully request reconsideration and withdrawal of the alternative obviousness rejection.

Accordingly, Applicant respectfully submits that the present inventive subject matter, as claimed in claims 1-7, is not rendered obvious by the combination of the Jerussi et al. patent with the Amey et al. patent. Applicant request reconsideration and withdrawal of this rejection.

**CONCLUSION**

In view of the foregoing, Applicant respectfully submits that the present claims are patentable over the prior art of record in this case and requests the Examiner to reconsider and withdraw the rejection of the claims and to allow all of the claims pending in this application.

If the Examiner has any questions or wishes to discuss this matter, the Examiner is welcomed to telephone the undersigned attorney.

Respectfully submitted,


**NATH & ASSOCIATES**

Date: January 22, 2003

**NATH & ASSOCIATES**

1030 Fifteenth Street, N.W.  
Sixth Floor  
Washington, D.C. 20005  
Tel: (202) 775-8383  
Fax: (202) 775-8396

GMN:JLM:jkh:24222-X3.roa.wpd



Gary M. Nath  
Reg. No. 26,965  
Jerald L. Meyer  
Reg. No. 41,194